Gina Mauro

Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

February 21st 2022

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

ASCO GU 2022: Breaking Down Bladder Cancer Results With Drs. Jonathan Rosenberg and Guru Sonpavde

February 19th 2022

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

Frontline Maintenance Avelumab Shows Consistent OS Benefit in Advanced Urothelial Cancer

February 18th 2022

The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

February 18th 2022

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC

February 17th 2022

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

Collaborations With Orthopedic Surgeons, Interventional Radiologists Key to Novel Approaches in Metastatic Bone Cancer

February 15th 2022

R. Lor Randall, MD, discusses the importance of collaborations between orthopedic surgeons and interventional radiologists, and how they are beginning to pick up steam in the United States for patients with metastatic bone cancer.

UCSF Showcases Potentially Game-Changing Trials Across Multiple Myeloma Settings

February 14th 2022

Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.

Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance

February 7th 2022

Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.

Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

February 4th 2022

Arpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient population.

Orca-T Reduces GVHD, Improves GVHD-Free RFS in Posttransplant Setting Across Hematologic Cancers

January 28th 2022

Arpita Gandhi, MD, discusses the background of Orca-T in further detail and how this type of treatment could revolutionize outcomes for patients with serious hematologic malignancies.

Gender, Racial, and Socioeconomic Status Disparities Linked With Incidence of Metastatic Bone Disease

January 26th 2022

R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.

Trastuzumab Deruxtecan Upholds 40% Improvement in OS in HER2+ Advanced Gastric/GEJ Cancer

January 20th 2022

Fam-trastuzumab deruxtecan-nxki demonstrated a 40% reduction in the risk of death compared with standard chemotherapy in patients with HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

FDA Grants Fast Track Status to CYNK-001 for AML

December 27th 2021

The FDA has granted Fast Track Designation to CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, for the potential treatment of patients with acute myeloid leukemia.

FDA Approves TLX591-CDx for Prostate Cancer Imaging

December 20th 2021

The FDA has approved the imaging product TLX591-CDx as a radioactive diagnostic agent for PET of prostate-specific membrane antigen positive lesions in patients with prostate cancer who have suspected metastasis who are candidates for initial definitive therapy, and in those with suspected recurrence based on elevated serum prostate-specific antigen level.

Pacritinib Shows Manageable Safety Profile in Cytopenic Myelofibrosis, Severe Thrombocytopenia

December 14th 2021

Treatment with pacritinib, when administered at 200 mg twice daily, had a comparable safety profile to best available therapy in patients with cytopenic myelofibrosis, including those with severe thrombocytopenia.

Luspatercept Shows Impressive Responses, Tolerability in Low-Risk MDS

December 14th 2021

Luspatercept-aamt produced more durable responses compared with placebo in patients with lower-risk myelodysplastic syndrome and anemia that is refractory to or ineligible for erythropoiesis-stimulating agent therapy.

Updates in AML and MPNs From ASH 2021: From Drs Srdan Verstovsek and Naval Daver

December 13th 2021

OncLive® speaks with Dr. Srdan Verstovsek on the pivotal data in myeloproliferative neoplasms, and Dr. Naval Daver on some intriguing findings in acute myeloid leukemia.

Cilta-Cel Continues to Impress With Durable and Deep Responses in Relapsed/Refractory Multiple Myeloma

December 13th 2021

Ciltacabtagene autoleucel elicited a 97.9% objective response rate and an 82.5% stringent complete response rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up.

Axi-Cel Demonstrates 60% EFS Improvement in Second-Line Relapsed/Refractory LBCL

December 13th 2021

Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.

Exciting Results Ignite in Multiple Myeloma and CLL at ASH 2021: Perspectives From Drs Nina Shah and Jacqueline Barrientos

December 12th 2021

OncLive® speaks with Dr. Nina Shah on some practice-changing multiple myeloma abstracts, and Dr. Jacqueline Barrientos on the latest in chronic lymphocytic leukemia.